This randomized controlled study will be the first to directly compare the glycemic control and treatment satisfaction achieved with a switch to semaglutide administration to those achieved by continuing with other GLP-1 receptor agonists in Japanese patients with type 2 diabetes. |
The study will make two different comparisons: plan A, a comparison of semaglutide and liraglutide; and plan B, a comparison of semaglutide and dulaglutide. |
The study is a multicenter, prospective, randomized, blinded-endpoint, parallel-group trial, although participants will not be blinded to their treatment. |
The study will be conducted at seven medical centers in a standard clinical practice setting, and will incorporate broad eligibility criteria, reflecting the real world. |
Digital Features
Introduction
Methods
Study Design
Sample Selection
Box 1: Inclusion Criteria
-
Japanese patients with T2D.
-
Age 20–89 years.
-
HbA1c 6.0–9.9%.
-
Body mass index ≥ 22 kg/m2.
-
Treatment with liraglutide or dulaglutide for at least 12 weeks before enrollment.
Box 2: Exclusion Criteria
-
Treatment with any GLP-1 receptor agonist other than liraglutide or dulaglutide.
-
Allergy to semaglutide.
-
Unstable diabetic retinopathy.
-
Current severe liver dysfunction or nephropathy.
-
Severe infection, trauma, and/or recent or planned surgery.
-
Severe ketosis.
-
Diabetic coma or pre-coma.
-
Pregnancy.
-
Incompatibility with the trial for other reasons, as determined by the physician.